⚠️ Serious warning: Nothing on this website is approved by any physician. Doz is only a tool to help physicians and to search drugs easily. Taking medicines without medical supervision can be fatal.

Ertugliflozin

ارتوگلیفلوزین

⚠ Unverified

🍽️ Alimentary Tract And MetabolismSGLT2 inhibitor

🤰 Pregnancy:Use with caution 🤱 Breastfeeding:Use with caution 👶 Children:Safety not established 👴 Older adults:Use with caution 🇮🇷 Not found in Iran list ⛔ 1 contraindications 🇺🇸 FDA approved (NDA) NDA209803 ATC A10BK04

Market / country: 🇺🇸 USA

Steglatro (US)

🧮 Dose calculator

Disease / regimen

Type 2 diabetes mellitus · Regimen source: FDA Steglatro · 2.2

• Correct volume depletion first. Withhold ≥4 days before surgery. FDA Steglatro · 2.1 FDA Steglatro · 2.3

Formulation

Age *

Weight (kg) (optional)

Enter age (weight is optional for this regimen).

🛡️ Safety & information

Contraindications

⛔ Hypersensitivity to ertugliflozin. FDA Steglatro · 4

Warnings

• Ketoacidosis (even with modest glucose); lower-limb amputation; volume depletion; genitourinary infections incl. urosepsis; hypoglycaemia with insulin or sulfonylureas. FDA Steglatro · 5

Renal adjustment

• eGFR < 45: eGFR <45: not recommended. FDA Steglatro · 2.2

Formulations

5 mg tablet — tablet 🇺🇸 USA FDA Steglatro · 3
15 mg tablet — tablet 🇺🇸 USA FDA Steglatro · 3

👥 Special populations

🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Steglatro · 8.1
“Risk Summary Based on animal data showing adverse renal effects, STEGLATRO is not recommended during the second and third trimesters of pregnancy.”
🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Steglatro · 8.2
“Risk Summary There is no information regarding the presence of STEGLATRO in human milk, the effects on the breastfed infant, or the effects on milk production.”
👶 ChildrenSafety not established
Label: safety and effectiveness in children have not been established. FDA Steglatro · 8.4
“Safety and effectiveness of STEGLATRO in pediatric patients under 18 years of age have not been established.”
👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Steglatro · 8.5
“… %, and 2.6% of patients treated with comparator, STEGLATRO 5 mg, and STEGLATRO 15 mg, respectively [see Warnings and Precautions (5.3) and Adverse Reactions (6.1) ] .”
⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.

🔗 Reference links

FDA (approval record)NDA209803
DailyMed (FDA label)FDA Steglatro
MedlinePlus (NIH)Ertugliflozin
WHO ATC/DDDA10BK04
Darooyab (Iran)❌ None

🇮🇷 Not found in Iran list Darooyab · search

Darooyab lists no registered dosage form or brand for this drug. This does not prove it is unavailable.

📚 Reference status for this drug

Shows which sources have references recorded for this drug and which do not.

FDA label (DailyMed)✅ Present
FDA Steglatro · 3 FDA Steglatro · 2.2 FDA Steglatro · 2.1 FDA Steglatro · 2.3 FDA Steglatro · 4 FDA Steglatro · 5 FDA Steglatro · SPL approval / marketing category FDA Steglatro · 8.1 FDA Steglatro · 8.2 FDA Steglatro · 8.4 FDA Steglatro · 8.5
UK SmPC (eMC / MHRA)❌ Not present
Published guideline❌ Not present
Licensed reference (medical school)❌ Not present
Iranian leaflet (IFDA)❌ Not present
Pharmacy website (secondary, unreliable)✅ Present
Darooyab · search
Clinical review⚠ Unverified